HPaCD against Alzheimer Disease
HP-beta-cyclodextrin (HPbCD) is currently in clinical trials against Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease (AD) and these trials
Author: kmwittkowski
Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation
A patent application by Knut M. Wittkowski (ASDERA LLC, US) entitled “Use of cyclodextrins in diseases and disorders involving phospholipid